90Y · B72.3 Against pancreatic cancer

Dosimetric and biological analysis

Minesh P. Mehta, Shrikant S. Kubsad, John F. Fowler, Ajit K. Verma, Jer Tsong Hsieh, Timothy J. Kinsella

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Nude mice xenografted with a human pancreatic carcinoma cell line were injected with yttrium-90 (90Y) conjugated to diethylene triaminepenta acetic acid (DTPA) alone, and DTPA covalently linked to a monoclonal antibody, B72.3. The animals were sacrificed in temporal sequence to evaluate isotope distribution. Dosimetry was carried out using the principles outlined in MIRD and ICRU Report 32. Results are expressed as percent uptake per unit mass in organs and tumor and as relative absorbed dose normalized to 9°Y uptake in liver at 7 hr. When conjugated to B72.3, an 8-fold increase in isotope localization in the tumor was noted by 24 hr. When the relative absorbed dose is calculated for 90Y and 90Y · B72.3, a 26-fold increase in tumor dose is noted for the 90Y conjugate. Normal tissues show no to modest (<5X) enhanced dose with 90Y · B72.3. B72.3, therefore, deserves further investigation as a potential monoclonal antibody for targeting therapeutic radioisotopes and possibly diagnostic radioisotopes to pancreatic cancer. Radiobiological aspects of the low dose rates from radioimmunotherapy are discussed.

Original languageEnglish (US)
Pages (from-to)627-631
Number of pages5
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume19
Issue number3
DOIs
StatePublished - 1990

Fingerprint

bioassay
Pancreatic Neoplasms
cancer
dosage
tumors
antibodies
acetic acid
Radioisotopes
Isotopes
Acetic Acid
isotopes
Monoclonal Antibodies
Radioimmunotherapy
Yttrium
Neoplasms
yttrium
cultured cells
liver
Nude Mice
organs

Keywords

  • Y
  • B72.3
  • Dosimetry
  • Monoclonal antibody
  • Pancreatic cancer
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

90Y · B72.3 Against pancreatic cancer : Dosimetric and biological analysis. / Mehta, Minesh P.; Kubsad, Shrikant S.; Fowler, John F.; Verma, Ajit K.; Hsieh, Jer Tsong; Kinsella, Timothy J.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 19, No. 3, 1990, p. 627-631.

Research output: Contribution to journalArticle

Mehta, Minesh P. ; Kubsad, Shrikant S. ; Fowler, John F. ; Verma, Ajit K. ; Hsieh, Jer Tsong ; Kinsella, Timothy J. / 90Y · B72.3 Against pancreatic cancer : Dosimetric and biological analysis. In: International Journal of Radiation Oncology, Biology, Physics. 1990 ; Vol. 19, No. 3. pp. 627-631.
@article{dafa2a769527476e9b033d1fa89b7dbb,
title = "90Y · B72.3 Against pancreatic cancer: Dosimetric and biological analysis",
abstract = "Nude mice xenografted with a human pancreatic carcinoma cell line were injected with yttrium-90 (90Y) conjugated to diethylene triaminepenta acetic acid (DTPA) alone, and DTPA covalently linked to a monoclonal antibody, B72.3. The animals were sacrificed in temporal sequence to evaluate isotope distribution. Dosimetry was carried out using the principles outlined in MIRD and ICRU Report 32. Results are expressed as percent uptake per unit mass in organs and tumor and as relative absorbed dose normalized to 9°Y uptake in liver at 7 hr. When conjugated to B72.3, an 8-fold increase in isotope localization in the tumor was noted by 24 hr. When the relative absorbed dose is calculated for 90Y and 90Y · B72.3, a 26-fold increase in tumor dose is noted for the 90Y conjugate. Normal tissues show no to modest (<5X) enhanced dose with 90Y · B72.3. B72.3, therefore, deserves further investigation as a potential monoclonal antibody for targeting therapeutic radioisotopes and possibly diagnostic radioisotopes to pancreatic cancer. Radiobiological aspects of the low dose rates from radioimmunotherapy are discussed.",
keywords = "Y, B72.3, Dosimetry, Monoclonal antibody, Pancreatic cancer, Radioimmunotherapy",
author = "Mehta, {Minesh P.} and Kubsad, {Shrikant S.} and Fowler, {John F.} and Verma, {Ajit K.} and Hsieh, {Jer Tsong} and Kinsella, {Timothy J.}",
year = "1990",
doi = "10.1016/0360-3016(90)90489-7",
language = "English (US)",
volume = "19",
pages = "627--631",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - 90Y · B72.3 Against pancreatic cancer

T2 - Dosimetric and biological analysis

AU - Mehta, Minesh P.

AU - Kubsad, Shrikant S.

AU - Fowler, John F.

AU - Verma, Ajit K.

AU - Hsieh, Jer Tsong

AU - Kinsella, Timothy J.

PY - 1990

Y1 - 1990

N2 - Nude mice xenografted with a human pancreatic carcinoma cell line were injected with yttrium-90 (90Y) conjugated to diethylene triaminepenta acetic acid (DTPA) alone, and DTPA covalently linked to a monoclonal antibody, B72.3. The animals were sacrificed in temporal sequence to evaluate isotope distribution. Dosimetry was carried out using the principles outlined in MIRD and ICRU Report 32. Results are expressed as percent uptake per unit mass in organs and tumor and as relative absorbed dose normalized to 9°Y uptake in liver at 7 hr. When conjugated to B72.3, an 8-fold increase in isotope localization in the tumor was noted by 24 hr. When the relative absorbed dose is calculated for 90Y and 90Y · B72.3, a 26-fold increase in tumor dose is noted for the 90Y conjugate. Normal tissues show no to modest (<5X) enhanced dose with 90Y · B72.3. B72.3, therefore, deserves further investigation as a potential monoclonal antibody for targeting therapeutic radioisotopes and possibly diagnostic radioisotopes to pancreatic cancer. Radiobiological aspects of the low dose rates from radioimmunotherapy are discussed.

AB - Nude mice xenografted with a human pancreatic carcinoma cell line were injected with yttrium-90 (90Y) conjugated to diethylene triaminepenta acetic acid (DTPA) alone, and DTPA covalently linked to a monoclonal antibody, B72.3. The animals were sacrificed in temporal sequence to evaluate isotope distribution. Dosimetry was carried out using the principles outlined in MIRD and ICRU Report 32. Results are expressed as percent uptake per unit mass in organs and tumor and as relative absorbed dose normalized to 9°Y uptake in liver at 7 hr. When conjugated to B72.3, an 8-fold increase in isotope localization in the tumor was noted by 24 hr. When the relative absorbed dose is calculated for 90Y and 90Y · B72.3, a 26-fold increase in tumor dose is noted for the 90Y conjugate. Normal tissues show no to modest (<5X) enhanced dose with 90Y · B72.3. B72.3, therefore, deserves further investigation as a potential monoclonal antibody for targeting therapeutic radioisotopes and possibly diagnostic radioisotopes to pancreatic cancer. Radiobiological aspects of the low dose rates from radioimmunotherapy are discussed.

KW - Y

KW - B72.3

KW - Dosimetry

KW - Monoclonal antibody

KW - Pancreatic cancer

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=0025195666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025195666&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(90)90489-7

DO - 10.1016/0360-3016(90)90489-7

M3 - Article

VL - 19

SP - 627

EP - 631

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 3

ER -